Analysts Set MediWound Ltd. (NASDAQ:MDWD) Price Target at $33.50

Shares of MediWound Ltd. (NASDAQ:MDWD) have been given an average rating of “Moderate Buy” by the six research firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $33.50.

MDWD has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a report on Wednesday, October 8th. Wall Street Zen upgraded MediWound from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. HC Wainwright restated a “buy” rating and issued a $36.00 price target (up from $31.00) on shares of MediWound in a research report on Friday, November 21st. Finally, Zacks Research raised shares of MediWound from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th.

Institutional Trading of MediWound

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rosalind Advisors Inc. lifted its stake in MediWound by 84.0% in the third quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company’s stock worth $13,498,000 after purchasing an additional 341,993 shares during the last quarter. Meitav Investment House Ltd. lifted its stake in shares of MediWound by 825.7% during the 3rd quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company’s stock worth $5,241,000 after acquiring an additional 260,116 shares during the last quarter. Millennium Management LLC lifted its stake in shares of MediWound by 355.6% during the 3rd quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock worth $3,160,000 after acquiring an additional 136,884 shares during the last quarter. Menora Mivtachim Holdings LTD. boosted its holdings in MediWound by 348.8% during the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 78,539 shares of the biopharmaceutical company’s stock valued at $1,415,000 after acquiring an additional 61,039 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in MediWound in the 3rd quarter valued at $1,042,000. 46.83% of the stock is owned by hedge funds and other institutional investors.

MediWound Price Performance

NASDAQ MDWD opened at $18.26 on Wednesday. MediWound has a 1-year low of $14.14 and a 1-year high of $22.50. The business has a 50 day simple moving average of $18.29 and a two-hundred day simple moving average of $18.44. The stock has a market capitalization of $202.50 million, a PE ratio of -9.61 and a beta of 0.07.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Thursday, November 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.57. MediWound had a negative net margin of 98.43% and a negative return on equity of 62.11%. The company had revenue of $5.43 million for the quarter, compared to the consensus estimate of $6.56 million. On average, analysts anticipate that MediWound will post -2.66 EPS for the current fiscal year.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.